Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study

[1]  Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.  A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular Carcinoma , 2009 .

[2]  S. Altekruse,et al.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[4]  P. Quaretti,et al.  Transarterial Chemoembolization for Hepatocellular Carcinoma with Drug-Eluting Microspheres: Preliminary Results from an Italian Multicentre Study , 2008, CardioVascular and Interventional Radiology.

[5]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[6]  Michael Höpfner,et al.  Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. , 2008, World journal of gastroenterology.

[7]  T. Wachs,et al.  CONSORT for reporting randomised trials in journal and conference abstracts , 2008 .

[8]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[9]  K. Kichikawa,et al.  Transcatheter Arterial Chemoembolization (TACE) with Lipiodol to Treat Hepatocellular Carcinoma: Survey Results from the TACE Study Group of Japan , 2008, CardioVascular and Interventional Radiology.

[10]  A. Gouliamos,et al.  Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma with Drug Eluting Beads: Results of an Open-Label Study of 62 Patients , 2008, CardioVascular and Interventional Radiology.

[11]  J. Kettenbach,et al.  Drug-Loaded Microspheres for the Treatment of Liver Cancer: Review of Current Results , 2008, CardioVascular and Interventional Radiology.

[12]  A. Venook,et al.  Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. , 2007, The oncologist.

[13]  K. Tai,et al.  A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  C. Porta,et al.  Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Lloyd,et al.  Doxorubicin eluting beads − 1: Effects of drug loading on bead characteristics and drug distribution , 2007, Journal of materials science. Materials in medicine.

[16]  J. Bruix,et al.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.

[17]  E. Cholongitas,et al.  Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies , 2007, CardioVascular and Interventional Radiology.

[18]  A. Lewis,et al.  Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. , 2006, Journal of vascular and interventional radiology : JVIR.

[19]  K. Hong,et al.  New Intra-arterial Drug Delivery System for the Treatment of Liver Cancer: Preclinical Assessment in a Rabbit Model of Liver Cancer , 2006, Clinical Cancer Research.

[20]  A. Lloyd,et al.  DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. , 2006, Journal of vascular and interventional radiology : JVIR.

[21]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[22]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[23]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[24]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[25]  J. Bruix,et al.  Prognostic prediction and treatment strategy in hepatocellular carcinoma , 2002, Hepatology.

[26]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[27]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.

[28]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.

[29]  J. Pignon,et al.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. , 1998, Journal of hepatology.

[30]  J. Bruix,et al.  Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution , 1998, Hepatology.

[31]  D. Guyader,et al.  Prospective randomized trial of chemoembolization versus intra‐arterial injection of 131I‐labeled–iodized oil in the treatment of hepatocellular carcinoma , 1997, Hepatology.

[32]  D. Heresbach,et al.  Chemoembolization of hepatocellular carcinomas a study of the biodistribution and pharmacokinetics of doxorubicin , 1992 .

[33]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[34]  D. Heresbach,et al.  Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. , 1992, Cancer.

[35]  Y. Liaw,et al.  Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. , 1988, Gastroenterology.

[36]  A. Tsiatis,et al.  Approximately optimal one-parameter boundaries for group sequential trials. , 1987, Biometrics.